Teva Pharmaceutical (Four Oncology R&D Assets) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Teva Pharmaceutical (Four Oncology R&D Assets) General Information

Description

Four oncology development programs of Teva Pharmaceutical Industries. The business assets are CEP-32496, a potent small molecule inhibitor of BRAF, EGFR and RET, CEP-40783, a potent, highly selective, pseudo-irreversible inhibitor of AXL and cMET, CEP-40125, a nanoformulation of a modified bendamustine with potential activity in solid tumors and TEV-44229, a potent, selective inhibitor of the atypical kinase PKCiota that is in preclinical studies.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Biotechnology
Acquirer
Ignyta
Primary Office
  • San Diego, CA 92121
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Teva Pharmaceutical (Four Oncology R&D Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.

Request a free trial

Teva Pharmaceutical (Four Oncology R&D Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.

Request a free trial